Chiasma (CHMA) announced that it is reducing its workforce by another 44%. The reductions will come mainly from &D and Administration. The action, expected to be completed this quarter, will save more than $7M per year in expenses. The company will record a one-time charge of $0.8M - 1.0M in Q3 for severance and related costs. The remaining headcount will be less than 25. CHMA plans to focus its resources on the continued development of Mycapssa (octreotide) capsules for the maintenance treatment of adults with acromegaly.